Pfizer Inc. (PFE) has experienced a decline of 0.07% in the aftermarket. However, the last trading session concluded at $42.32 with a decline of 0.24%.
Japan’s MHLW Approves Pfizer’s Cibinqo
PFE announced on 30th September 2021 that The Japanese Ministry of Health, Labour, and Welfarehas authorized CIBINQO. It is an oral, once-daily Janus kinase inhibitor, for the treatment associated with chronic pain atopic dermatitis. It usually occurs in adults and youth aged 12 years and older who have had an insufficient response to existing therapies.
There have been few treatment choices for moderate – to – severe atopic dermatitis in Japan. The company expects CIBINQO to have a significant impact on the lives of individuals living with this persistent and frequently debilitating disease. The results of 1,513 patients across four Phase 3 trials spanning from 12 to 16 weeks of therapy, as well as a long-term extension study from a comprehensive clinical trial program, led to the approval of CIBINQO in Japan.
Positive Top-Line Results of Pfizer’s Phase 3 Study
PFE published positive results regarding the Phase 3 study on 29th September 2021. PREVNAR 20TM (Pneumococcal 20-valent Conjugate Vaccine) is safe and immunogenic in individuals 65 years of age. When given simultaneously, the responses evoked by PREVNAR 20 for all 20 serotypes. Moreover, the seasonal influenza vaccination was non-inferior to those generated by the vaccines when given one month apart (the study’s primary immunogenicity goals).
When the vaccinations were given together, the safety profile of PREVNAR 20 was comparable to when they were given individually. These findings indicate that these two vaccines may be given at the same time without compromising immune protection. Furthermore, this study adds to the growing body of data.
PFE announced Positive Phase 2 Results
PFE announced positive phase 2 results on 28th September 2021. VLA15, a Lyme disease vaccine candidate, had further good Phase 2 findings, including a booster response. VLA15-202 is a Phase 2 trial that looks at the immunogenicity and safety of VLA15 in a Month. The research included 246 healthy people in the United States, ranging in age from 18 to 65. Moreover, the trial accomplished its primary goal of establishing that VLA15.
Antibody titers fell subsequently across both groups, remaining above baseline but demonstrating the requirement for a booster approach, according to a follow-up examination at Month 18. Lastly, VLA15 is safe and well-tolerated at all dosages and in all age groups. There were no associated Serious Adverse Events (SAEs) in any of the treatment groups.
